Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 2/20 | 0.35 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888984 | 0.83 | G6PD (0.48) | TP53HSD17B10G6PDTSHRCDC7 | |
| SCHEMBL1884552 | 0.80 | G6PD (0.37) | TP53HSD17B10G6PDLMNAPAK1 | |
| SCHEMBL2115552 | 0.79 | PAK1 (0.40) | TP53HSD17B10G6PDTSHRCYP1A2 | |
| SCHEMBL754882 | 0.79 | ALDH1A1 (0.39) | TP53HSD17B10G6PDTSHRALDH1A1 | |
| SCHEMBL2888365 | 0.77 | G6PD (0.35) | TP53HSD17B10G6PDCDC7DBF4 | |
| SCHEMBL2118555 | 0.77 | PAK1 (0.48) | TP53HSD17B10TSHRCYP1A2CDC7 | |
| SCHEMBL31186595 | 0.76 | CDC7 (0.64) | HSD17B10CYP1A2CDC7DBF4LMNA | |
| SCHEMBL21639749 | 0.76 | CDC7 (0.64) | HSD17B10CYP1A2CDC7DBF4LMNA | |
| SCHEMBL130799 | 0.76 | MAP3K5 (0.56) | TP53HSD17B10MAP3K5CYP1A2ALDH1A1 | |
| SCHEMBL763254 | 0.74 | MAP3K5 (0.39) | TP53HSD17B10MAP3K5CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250076302-A1 | DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES | THE CLEVELAND CLINIC FOUNDATION | 2025-03-06 | — | — | US | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240368505-A1 | FLUORINE-FREE CLEANING AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF | Tan Kah Kee Innovation Laboratory (CN) | 2024-11-07 | — | — | US | claimed |
| CN-118879891-A | Method for evaluating PE (polyethylene) based on intestinal flora | 广州市番禺区妇幼保健院(广州市番禺区何贤纪念医院) | 2024-11-01 | — | — | CN | claimed |
| CN-116731798-A | Fluorine-free cleaning agent, and preparation method and application thereof | 嘉庚创新实验室 | 2023-09-12 | — | — | CN | claimed |
| WO-2023133876-A1 | FLUORINE-FREE CLEANING AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF | 嘉庚创新实验室 | 2023-07-20 | — | — | WO | claimed |
| CN-114317127-B | Fluorine-free cleaning agent, and preparation method and application thereof | 嘉庚创新实验室 | 2023-07-04 | — | — | CN | claimed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| CN-114558061-B | Loquat leaf extract and preparation method and application thereof | 浙江大学 | 2023-04-04 | — | — | CN | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | claimed |
| WO-2003105862-A1 | IN-VIVO ENERGY DEPLETING STRATEGIES FOR KILLING DRUG-RESISTANT CANCER CELLS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-12-24 | — | — | WO | claimed |
| WO-2003076894-A2 | A RAPID IMMUNOCHEMICAL PROCESS FOR MEASURING THIOPURINE METHYLTRANSFERASE REACTION PRODUCTS | BIOLOGIX DIAGNOSTICS, LLC (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030170764-A1 | Rapid, immunochemical process for measuring thiopurine methyltransferase | BIOLOGIX DIAGNOSTICS, LLC | 2003-09-11 | — | — | US | claimed |
| US-5733915-A | CORTICOIDS AND AZATHIOPRINE | GLAXO WELLCOME INC. (US) | 1998-03-31 | — | — | US | claimed |
| US-RE35558-E | (2R)-2-[di(2-propyl)phosphonyylmethoxy]-3-P-toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1997-07-08 | — | — | US | claimed |
| US-5438130-A | Fucosylated guanosine disulfates as excitatory amino acid antagonists | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-08-01 | — | — | US | claimed |
| US-5352786-A | Di(2-propyl)esters of 1-fluoro-2-phosphonomethoxy-3-P-to-luenesulfonyloxypropanes, their producing and utilization | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1994-10-04 | — | — | US | claimed |
| WO-1994015622-A1 | NUCLEOSIDE DERIVATIVES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS | CAMBRIDGE NEUROSCIENCE (US) | 1994-07-21 | — | — | WO | claimed |
| EP-0044928-B1 | 1,4;3,6-DIANHYDRO-HEXITE-NITRATE SUBSTITUTED BY PURINE BASES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | Dr. Willmar Schwabe GmbH & Co. (DE) | 1985-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | TP53 2728/4885HSD17B10 1289/4885MAP3K5 4429/4885 |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | TP53 645/4885HSD17B10 3818/4885MAP3K5 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.